Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and Panitumumab in Metastatic Colorectal Cancer
NCT02008383Phase 1Completed
- Sponsor
- John Strickler
- Start
- Jan 2014
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cabozantinib in metastatic colorectal cancer (mCRC) (2 arms), sponsored by John Strickler. Primary endpoints: Recommended Phase II Dose at 1 year and Objective Response Rate. Started Jan 2014; status: completed.
02
Drugs
cabozantinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02008383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02008383.